Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To estimate canine interleukin-8 (cIL-8) levels in blood plasma samples, a sandwich enzyme linked immunosorbent assay (ELISA) was established. For the development of the sandwich ELISA, polyclonal anti-cIL-8 (capturing), biotinylated anti-cIL-8 (developing) antibodies and glutathione-S-transferase/cIL-8 (
GST
/cIL-8) fusion protein as an antigen were used. cIL-8 in the fusion protein of
GST
/cIL-8 was detected in a dose dependent manner. The lowest limit of
GST
/cIL-8 detectable by this method was 2 ng/ml of
GST
/cIL-8 (containing; 0.470 ng/ml of cIL-8). IL-8 levels in the plasma samples from apparently healthy dogs were less than 0.470 ng/ ml. Higher levels of IL-8 were detected in the plasma samples of dogs with
cystitis
, dermatitis, and gastric cancer. These results suggest that the determination of cIL-8 by the sandwich ELISA is useful in diagnosis of inflammatory diseases in dogs.
...
PMID:Establishment of a sandwich enzyme linked immunosorbent assay for canine interleukin-8. 903 76
The present study was designed to describe the expression of the
glutathione S-transferase
/glutathione system in squamous cell carcinoma of the bladder in a population in Egypt. The glutathione-S transferase activity was significantly higher in bladder cancer specimens (n = 40) in comparison with schistosomiasis
cystitis
tissue (n = 42) (4-fold, p = 1 x 10(-12)) and with healthy control samples (n = 9) (10-fold, p = 1 x 10(-6)). The glutathione content was also significantly higher in bladder cancer than in
cystitis
tissue (2-fold, p = 8 x 10(-6)) and in control samples (6-fold, 8 x 10(-6)). When control mucosa and
cystitis
samples were compared, 2-fold increased values were obtained for glutathione-S transferase (p = 4 x 10(-3)) and glutathione (p = 1 x 10(-3)) in schistosomiasis bladder tissue. Results describe an over-expression of glutathione-S transferase and glutathione levels in squamous cell carcinoma of the bladder, and indicate a possible role in chemoresistance to pharmacological therapy.
...
PMID:Expression of glutathione S-transferase activity and glutathione content in squamous cell carcinoma of bladder associated with schistosomiasis in a population in Egypt. 906 83
Hemorrhagic cystitis and diffuse inflammation of the bladder, common side effects of cyclophosphamide (CY) treatment, have been linked to the generation of acrolein derived from CY metabolism. Metabolic removal of acrolein involves multiple pathways, which include reduction, oxidation, and conjugation with glutathione. Herein, we tested the hypothesis that
glutathione S-transferase
P (GSTP), the
GST
isoform that displays high catalytic efficiency with acrolein, protects against CY-induced urotoxicity by detoxifying acrolein. Treatment of wild-type (WT) and mGstP1/P2 null (GSTP-null) mice with CY caused hemorrhagic
cystitis
, edema, albumin extravasation, and sloughing of bladder epithelium; however, CY-induced bladder ulcerations of the lamina propria were more numerous and more severe in GSTP-null mice. CY treatment also led to greater accumulation of myeloperoxidase-positive cells and specific protein-acrolein adducts in the bladder of GSTP-null than WT mice. There was no difference in hepatic microsomal production of acrolein from CY or urinary hydroxypropyl mercapturic acid output between WT and GSTP-null mice, but CY induced greater c-Jun NH(2)-terminal kinase (JNK) and c-Jun, but not extracellular signal-regulated kinase or p38, activation in GSTP-null than in WT mice. Pretreatment with mesna (2-mercaptoethane sulfonate sodium) abolished CY toxicity and JNK activation in GSTP-null mice. Taken together, these data support the view that GSTP prevents CY-induced bladder toxicity, in part by detoxifying acrolein. Because polymorphisms in human GSTP gene code for protein variants differing significantly in their catalytic efficiency toward acrolein, it is likely that GSTP polymorphisms influence CY urotoxicity. In addition, pretreatment with dietary or nutrient inducers of GSTP may be of use in minimizing bladder injury in patients undergoing CY therapy.
...
PMID:Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. 1969 94
The protective roles of lipoic acid (LA)/vitamin C (VC) and mesna on preventing cyclophosphamide (CYP)-induced haemorrhagic
cystitis
(HC) were investigated. Swiss mice were divided into five groups randomly. HC was induced by a single dose of CYP injection (150-mg kg(-1) bodyweight). Group I was injected with saline (four times in total) throughout as control group. Group II received CYP and three equal doses of saline. Group III received CYP and three doses of mesna, whereas Group IV (or Group V) received CYP, mesna + two doses of VC (or LA). All injections were performed intraperitoneally. After 24 h of
cystitis
induction, the bladders were collected for all the experiments. Histological characterization showed that CYP injection resulted in severe HC. Reactive oxygen species (ROS) and thiobarbituric acid reactive substances' levels were increased in CYP group. The activities of antioxidant enzymes, e.g. superoxide dismutase, catalase,
glutathione S-transferase
and glutathione peroxidase, were inhibited significantly in CYP groups, respectively. In addition, activation of c-jun N-terminal kinases (JNK) and p38 mitogen-activated protein kinase (MAPK) may be involved in the mechanism of CYP-induced HC but not extracellular signal regulated kinases (ERK). Significant suppression of p38 phosphorylation on Group V suggests that LA and mesna may have synergistic beneficial effect. In Groups III-V, all the parameters of HC and oxidative stress were inhibited significantly. Taking together, we found that these results illustrated that ROS play an important role on CYP-induced HC and the administration of LA/VC with mesna may have therapeutic potential against CYP-induced bladder HC.
...
PMID:Protective effects of lipoic acid and mesna on cyclophosphamide-induced haemorrhagic cystitis in mice. 2365 Jan 19
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of hematopoietic stem cell transplantation (HSCT). Further improvement could be achieved through genotype-guided BU dose adjustments. To investigate this aspect, polymorphism within glutathione S transferase genes were assessed. Particularly, promoter haplotypes of the glutathione S transferase A1 (
GSTA1
) were evaluated
in vitro,
with reporter gene assays and clinically, in a pediatric multi-center study (N =138) through association with BU pharmacokinetics (PK) and clinical outcomes. Promoter activity significantly differed between the
GSTA1
haplotypes (p<0.001) supporting their importance in capturing PK variability. Four
GSTA1
diplotype groups that significantly correlated with clearance (p=0.009) were distinguished. Diplotypes underlying fast and slow metabolizing capacity showed higher and lower BU clearance (ml/min/kg), respectively.
GSTA1
diplotypes with slow metabolizing capacity were associated with higher incidence of sinusoidal obstruction syndrome, acute graft versus host disease and combined treatment-related toxicity (p<0.0005). Among other
GST
genes investigated,
GSTP1 313GG
correlated with acute graft versus host disease grade 1-4 (p=0.01) and
GSTM1 non-null
genotype was associated with hemorrhagic
cystitis
(p=0.003). This study further strengthens the hypothesis that
GST
diplotypes/genotypes could be incorporated into already existing population pharmacokinetic models for improving first BU dose prediction and HSCT outcomes. (N
o
Clinicaltrials.gov identifier: NCT01257854. Registered 8 December 2010, retrospectively registered).
...
PMID:GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. 2920 8